

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
18 September 2003 (18.09.2003)

PCT

(10) International Publication Number
WO 03/076400 A1

(51) International Patent Classification⁷: C07D 211/58, 401/04, 207/14, 403/04, A61K 31/4545, A61P 35/00, C12Q 1/34

(21) International Application Number: PCT/EP03/02514

(22) International Filing Date: 11 March 2003 (11.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: 60/363,799 13 March 2002 (13.03.2002) US

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ANGIBAUD, Patrick, René [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). PILATTE, Isabelle, Noëlle, Constance [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). VAN BRANDT, Sven, Franciscus, Anna [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). ROUX, Bruno [FR/FR]; Janssen-Cilag S.A., 1, rue Camille Desmoulins, TSA 91003, F-92787 Issy-les-Moulineaux Cedex 9 (FR). TEN HOLTE, Peter [NL/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VERDONCK, Marc, Gustaaf, Celine [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). MEERPOEL, Lieven [BE/BE]; Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). DYATKIN, Alexey, Borisovich [RU/US]; Johnson & Johnson Pharmaceutical Research and Development, L.L.C., Welsh and McKean Roads, Spring House, PA 19477 (US).

(74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Karen Vermuyten GA4736, J & J Patent Law Department, Turnhoutseweg 30, B-2340 Beerse (BE).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
- of inventorship (Rule 4.17(iv)) for US only


Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

[Continued on next page]

WO 03/076400 A1

(54) Title: NEW INHIBITORS OF HISTONE DEACETYLASE



(I)

(57) Abstract: This invention comprises the novel compounds of formula (I) wherein n, t, R¹, R², R³, R⁴, L, Q, X, Y, Z and have defined meanings, having histone deacetylase inhibiting enzymatic activity; their preparation, compositions containing them and their use as a medicine.